Trace Medical LiViliti Acquisition: CPAP Hygiene Deal

The Trace Medical LiViliti acquisition pairs a small CPAP hygiene innovator with a national respiratory equipment services company. On 12 October 2026, Trace Medical announced that it has acquired a majority interest in LiViliti Health Products, the Sarasota, Florida maker of CPAP accessories whose Paptizer 360 device received FDA 510(k) clearance earlier this year. Financial terms were not disclosed.

The deal is the new development. The clearance was granted in April 2026, and Trace Medical had already invested in LiViliti in December 2025. This report sets out the timeline, what the device is cleared to do, and what the announcement leaves out.

Key facts on the Trace Medical LiViliti acquisition

• Deal: Trace Medical acquired a majority interest in LiViliti Health Products. It builds on an existing strategic investment.
• Announced: 12 October 2026.
• Product: Paptizer 360, a Class II respiratory accessory microbial reduction device for compatible CPAP equipment.
• Clearance: 510(k) K252471, decided on 29 April 2026 according to the FDA database.
• Not disclosed: purchase price, the size of the majority stake, closing date and deal structure.

Timeline of the Trace Medical LiViliti acquisition

• December 2025: Trace Medical took an equity stake in LiViliti, with amounts undisclosed, and the companies planned a joint go-to-market effort from early 2026.
• 29 April 2026: the FDA cleared the Paptizer 360 through the 510(k) route.
• 6 May 2026: trade press reported the clearance, with LiViliti’s chief executive calling the device ozone-free.
• 12 October 2026: Trace Medical announced the majority acquisition.

What the Paptizer 360 is cleared to do in the Trace Medical LiViliti acquisition

The detail matters because the announcement describes the technology only as clinical-grade respiratory hygiene technology. The FDA database lists the Paptizer 360 as an adjunct to reduce bacterial populations on certain compatible home-use CPAP mask cushions after cleaning. It is an over-the-counter, single-patient device. It must not replace the manufacturer’s recommended cleaning. According to the clearance record, testing was done on one mask cushion model, and the indications describe a two-log, or 99%, reduction in the laboratory for six bacterial strains. The record also states that any correlation with clinical outcomes has not been established. The predicate device was SoClean 3+, which the FDA had authorised through its De Novo route.

In plain terms, the clearance supports use as a supplement to cleaning. It does not claim that using the device prevents infections, and the record says as much. The details of how it reduces bacteria were not described in the announcement, although the company has said it is ozone-free. Readers can look at the FDA’s 510(k) database entry K252471 for the clearance record, and the 510(k) pathway is explained on the FDA site.

Why Trace Medical wants LiViliti: the Trace Medical LiViliti acquisition rationale

Trace Medical, founded in 2004, describes itself as a national leader in advanced respiratory rentals and biomedical services. It serves skilled nursing and rehabilitation facilities, hospice and home medical equipment providers. LiViliti, founded in 2019, develops CPAP and respiratory accessories focused on hygiene, comfort and compliance. The announcement says the deal combines LiViliti’s equipment technology with Trace Medical’s nationwide distribution, servicing infrastructure and provider reach.

Executives were quoted on the logic. Trace Medical chief executive Greg Apostolou said LiViliti had shown exceptional innovation in patient safety, equipment hygiene and therapy adherence, and that together the companies are raising the standard of care for CPAP users and health systems. LiViliti founder and chief executive Brian Sharpe said the partnership provides the scale, logistical expertise and distribution power to make the technology broadly accessible. Those are company statements.

CPAP hygiene context for the Trace Medical LiViliti acquisition

As general background, not a claim from either company, CPAP users are normally told by manufacturers to clean masks, tubing and humidifier chambers on a regular schedule, usually with mild soap and water. In practice, cleaning is easy to skip, and facilities that rent equipment must also manage cleaning between patients under their own protocols. Products that add a convenient step have therefore found a market, and the earlier SoClean device, the predicate for the Paptizer 360, showed that regulators will clear such devices as adjuncts when the claims stay modest. Whether any of these products changes infection rates is a separate question that the clearance does not answer, so providers should follow the manufacturer’s instructions for their own equipment.

Our assessment of the Trace Medical LiViliti acquisition

In our assessment, the strategic fit is clear. CPAP therapy for obstructive sleep apnoea is long-term, and equipment cleaning is a recurring concern for patients and for the facilities that rent and service devices. A hygiene product that fits into a rental-and-service business can reach customers without building a new sales force. The National Heart, Lung, and Blood Institute provides background on sleep apnoea for general readers. The open question is demand: the clearance is narrow, with testing on one mask cushion model, and the claims are laboratory-based. How widely the device is used will depend on compatibility, price and whether providers see value in an adjunct rather than a replacement for cleaning.

What the Trace Medical LiViliti acquisition leaves unanswered

• The price and the size of the stake.
• Whether Trace Medical plans to buy the rest of LiViliti.
• Which CPAP models beyond the tested cushion will be supported.
• Pricing, reimbursement and launch plans for the Paptizer 360 across Trace Medical’s provider network.
• Clinical data on whether bacterial reduction improves outcomes. The FDA record says this has not been established.

For other recent MedTech deals, see our reports on the STERIS and Xodus Medical acquisition, the Viatris and Pacira acquisition and Axogen’s BioCircuit purchase, or browse more medical device news.

Frequently asked questions

What is the Trace Medical LiViliti acquisition?

Trace Medical announced on 12 October 2026 that it acquired a majority interest in LiViliti Health Products, a CPAP accessory maker based in Sarasota, Florida.

How much did Trace Medical pay in the Trace Medical LiViliti acquisition?

Financial terms were not disclosed.

What is the Paptizer 360?

A Class II device cleared as an adjunct to reduce bacteria on certain compatible home CPAP mask cushions after cleaning. It does not replace manufacturer cleaning.

When did the Paptizer 360 receive FDA clearance?

The FDA database lists a decision date of 29 April 2026. The acquisition came afterwards.

Does the Trace Medical LiViliti acquisition include the whole company?

No. It is a majority interest, and the size of the stake was not disclosed.

How we reported this: we relied on the companies’ announcement of 12 October 2026, their earlier December 2025 announcement and the FDA clearance record. Company claims are the companies’. Last updated: 13 October 2026. This article is news reporting and not investment or medical advice.